Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE